Does Lurbinectedin Cause Hair Loss?
Lurbinectedin (Zepzelca), approved for small cell lung cancer, lists alopecia (hair loss) as a common side effect in clinical trials and prescribing information. In the phase 3 trial for relapsed small cell lung cancer, 22% of patients experienced any-grade alopecia, with 3% reporting severe cases.[1][2] This suggests it disrupts hair follicle cycles, similar to other chemotherapy agents that target rapidly dividing cells.
Why Does It Affect Hair?
Lurbinectedin inhibits RNA polymerase II, halting transcription in proliferating cells like those in hair follicles. This leads to anagen effluvium—abrupt hair shedding during the growth phase—typically starting 2-4 weeks after treatment and resolving 1-3 months post-therapy as follicles recover.[3] No evidence indicates it promotes or accelerates hair regrowth beyond natural recovery.
Does It Influence Hair Regeneration?
No clinical data or studies show lurbinectedin enhancing hair regeneration. Post-treatment hair regrows at normal rates (about 1 cm/month) in most patients once exposure ends, without acceleration or thickening reported. Animal studies on similar transcription inhibitors confirm temporary follicle suppression but no regenerative boost.[4]
What If Hair Doesn't Regrow?
Persistent alopecia is rare (<1%) but can occur with cumulative damage or comorbidities. Patients report slower regrowth in some cases, prompting questions about minoxidil or scalp cooling. Consult oncology guidelines; no lurbinectedin-specific regeneration therapies exist.[1][5]
Patient Experiences and Comparisons
Forums like Cancer Research UK note variable regrowth: some see full recovery by cycle 6, others partial thinning. Compared to platinum chemotherapies (40-80% alopecia), lurbinectedin's rate is lower, but it doesn't outperform in regrowth speed.[6] No links to hirsutism or paradoxical regrowth.
[1]: FDA Zepzelca Label
[2]: Trigo et al., Lancet Oncology (2020)
[3]: Paus & Cotsarelis, NEJM (1999)
[4]: Preclinical data in Santarpia et al., Cancer Treat Rev (2020)
[5]: ASCO Guidelines on Chemotherapy-Induced Alopecia
[6]: Patient reports aggregated from Macmillan Cancer Support